Comprehensive antibody profiling of mRNA vaccination in children

While children have been largely spared from COVID-19 disease, the emergence of viral variants of concern (VOC) with increased transmissibility, combined with fluctuating mask mandates and school re-openings have led to increased infections and disease among children. Thus, there is an urgent need t...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2022-01
Main Authors: Bartsch, Yannic C, St Denis, Kerri J, Kaplonek, Paulina, Kang, Jaewon, Lam, Evan C, Burns, Madeleine D, Farkas, Eva J, Davis, Jameson, Boribong, Brittany, Edlow, Andrea G, Fasano, Alessio, Shreffler, Wayne, Dace Zavadska, Johnson, Marina, Goldblatt, David, Balazs, Alejandro B, Yonker, Lael M, Alter Galit
Format: Article
Language:English
Subjects:
Antibodies
Children
Conflicts of interest
COVID-19
COVID-19 vaccines
Immune response (humoral)
mRNA
Pandemics
Phagocytes
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:While children have been largely spared from COVID-19 disease, the emergence of viral variants of concern (VOC) with increased transmissibility, combined with fluctuating mask mandates and school re-openings have led to increased infections and disease among children. Thus, there is an urgent need to roll out COVID-19 vaccines to children of all ages. However, whether children respond equivalently to adults to mRNA vaccines and whether dosing will elicit optimal immunity remains unclear. Given the recent announcement of incomplete immunity induced by the pediatric dose of the BNT162b2 vaccine in young children, here we aimed to deeply profile and compare the vaccine-induced humoral immune response in 6-11 year old children receiving the pediatric (50μg) or adult (100μg) dose of the mRNA-1273 vaccine compared to adults and naturally infected children or children that experienced multi inflammatory syndrome in children (MIS-C) for the first time. Children elicited an IgG dominant vaccine induced immune response, surpassing adults at a matched 100μg dose, but more variable immunity at a 50μg dose. Irrespective of titer, children generated antibodies with enhanced Fc-receptor binding capacity. Moreover, like adults, children generated cross-VOC humoral immunity, marked by a decline of omicron receptor binding domain-binding, but robustly preserved omicron Spike-receptor binding, with robustly preserved Fc-receptor binding capabilities, in a dose dependent manner. These data indicate that while both 50μg and 100μg of mRNA vaccination in children elicits robust cross-VOC antibody responses, 100μg of mRNA in children results in highly preserved omicron-specific functional humoral immunity. Competing Interest Statement G.A. is a founder and equity holder of Seromyx Systems, a company developing a platform technology that describes the antibody immune response. G.A. is an employee and equity holder of Leyden Labs, a company developing pandemic prevention therapeutics. G.A.s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors have declared that no conflicts of interest exist.
DOI:10.1101/2021.10.07.463592